18 - 20 June, 2019 | Crowne Plaza Zurich, Switzerland

Main Conference Agenda Day 2

8:30 am - 9:00 am Morning Coffee and Registration

8:55 am - 9:00 am Pharma IQ Welcome

9:00 am - 9:10 am Chairman's Summary of Day One

9:10 am - 9:55 am The Limits of Serialisation and Traceability: Why There are No Holistic Counterfeit Drug Solutions

Everyone is aware of the troubling growth trend in the illicit pharmaceutical trade, and while we all agree that more needs to be done to protect patients, serialisation compliance will only be part of the solution. Neither Governments nor drug companies should be in any doubt - serialisation by itself will not be enough to safeguard the pharma supply chain and prevent illicit pharmaceutical trade, and thus, patient health risk.

- Discuss where item-level serialisation fits into the patient health protection strategy, and why it is not a solution in itself
- Analyse what combination of technologies is needed to fight counterfeiting
- Examine the impact of pharmaceutical product identification and traceability at the formulation level, and as a result, how pharmaceutical companies can better monitor patient impact

10:00 am - 10:45 am Brand Protection and Anti-Counterfeit as Leverage to Improve the Supply Chain

- Analyse the global serialisation requirements: How can companies prepare for global compliance with differences in regional requirements?
- Discuss how to translate serialisation compliance into a brand protection asset rather than a cost
- Identify the limitations of serialisation data: First and last touch supply chain visibility, and what can we do to close the transit gap?

10:40 am - 11:10 am Morning Coffee Break

11:10 am - 11:50 am E-Commerce: connecting an unconnected Internet ecosystem

  • The rising tide of fake pharmacy websites
  • How the Internet stakeholders need to become more connected
  • There is no silver bullet just lots of small rounds – what needs to be done
  • Stemming public demand by raising awareness is key

11:50 am - 12:30 pm Open Forum Discussion: Protecting Pharmaceutical Trade in an Increasingly Online Market

- Examine the ‘internetisation’ of healthcare and what it means for global supply chain security
- Discuss the cost benefit analysis of internet supply for pharmaceutical trade and market penetration
- Identify current solutions and strategies to protect your brand in the digital marketplace

12:30 pm - 1:30 pm Networking Lunch

1:30 pm - 2:10 pm Understanding the End-User Paradigm: Patient Impact Perspective on Anti-Counterfeit Strategies

- Address public perception of company anti-counterfeit and brand protection strategies, and the impact on governmental and patient collaboration
- Examine the impact of falsified and counterfeit medications on patient health outcomes and brand value
- Discuss the benefits of centralising the patient in your anti-counterfeit and brand protection strategy

2:10 pm - 2:50 pm Securing the Supply of Controlled Substances Globally

- Discuss the inherent constraints and opportunities in managing small patient population drugs on a global basis
- Understand the nature of controlled substance supply with reference to the US and EU markets
- Discuss the impact of limited patient populations: Know your patients, know your product (security!)
- Identify trends in demand and supply as a method for product risk managment

2:50 pm - 3:20 pm Afternoon Coffee Break

3:20 pm - 4:00 pm Understanding Cross-Border Collaboration and Impact – The WCO’s Approach to Building an Anti-Counterfeit Strategy

- Examine the challenge of regional market penetration: Do you manage the supply chain from afar or work with regional partners?
- Identify best strategies for coping with regional market importation requirements where you have less of an established brand presence and supply network
- Pinpoint how to identify suspicious import and export activities, and discuss next steps in process identification

4:00 pm - 4:45 pm Scenario Roundtables: Interrupting Counterfeit Networks and Strengthening Supply Chains: Balancing Investigations and Regulation

- Examine how markets outside of the EU are identifying illicit pharmaceutical trade and brand infringements without FMD serialisation
- Discuss the role of a field-based approach in counterfeit market interruption: Why local partnerships generate stronger results
- Map out where responsibility for investigation implementation sits: With the brand offshore, or with local market partners, and how to balance the associated risks